Detection of feline herpesvirus antibodies based on gB protein

By developing recombinant antibodies based on gB protein, the problem of low specificity of the diagnosis method of feline herpes virus FHV-1 in the prior art was solved, and high affinity and high specificity detection was achieved, ensuring the accurate diagnosis of feline herpes virus.

CN116693665BActive Publication Date: 2024-11-05SHENZHEN HERZ LIFE SCI TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310803269.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-30
Publication Date
2024-11-05
Estimated Expiration
2043-06-30

AI Technical Summary

Technical Problem

The existing diagnostic methods for feline herpes virus FHV-1 have low specificity and false positive problems, and cannot effectively detect infected FHV serum antibodies, resulting in difficulty in diagnosis.

Method used

Recombinant antibodies based on gB protein were developed, and specific detection was carried out through indirect immunofluorescence and indirect ELISA, etc., to provide high affinity and high specificity recombinant antibodies against type I feline herpes virus.

Benefits of technology

The specific detection of FHV virus is achieved, which improves the sensitivity and specificity of diagnosis, and ensures the accuracy of the detection results. In particular, the binding affinity of Ab-FHV gB-3 antibody and FHV virus is the highest, and it is suitable for feline herpes virus. specific detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004322101480000081
    Figure BDA0004322101480000081
  • Figure BDA0004322101480000082
    Figure BDA0004322101480000082
  • Figure BDA0004322101480000091
    Figure BDA0004322101480000091
Patent Text Reader

Abstract

The present invention relates to the field of in vitro detection technology, and in particular to antibodies for detecting feline herpes virus based on gB protein. The present invention constructs a phage single-chain antibody library by phage display technology, and screens 5 single-chain antibodies that can specifically bind to FHV-I after enrichment and sequencing. Five recombinant antibodies are obtained by molecular biology technology, among which the recombinant antibody Ab-FHV gB-3 has the highest affinity and specificity, and can be widely used in the specific detection of feline herpes virus FHV.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of in vitro detection, and in particular to an antibody for detecting feline herpes virus based on gB protein. Background Art

[0002] Feline Herpesvirus (FHV) type I belongs to the Herpesviridae family, Alpha herpesvirinae subfamily, and Varicellavirus genus. It is a double-stranded DNA virus. FHV-1 mainly infects kittens and can be transmitted by direct contact and indirect contact. After infection with the FHV virus, it can replicate in the mucosal cells of the upper respiratory tract and cause clinical symptoms such as fever, depression, coughing, sneezing, and even complications such as chronic sinusitis and keratoconjunctivitis. The mortality rate of kittens can reach 50%. In addition, dogs and wild cats such as cheetahs can also be infected with FHV, causing significant economic losses to the wildlife and pet industries.

[0003] The FHV genome contains 23 virion-associated proteins, among which gB protein is essential for viral replication and infection and is called an essential glycoprotein. gB is a highly conserved envelope glycoprotein that has high homology among different strains of herpesvirus and plays an important role in inducing high titer neutralizing antibodies and inhibiting viral replication.

[0004] The clinical symptoms of respiratory diseases caused by FHV-1 are similar to those caused by several other viruses, so it cannot be judged only from clinical symptoms. At present, the main diagnostic methods for FHV-1 are virus isolation and identification, immunofluorescence detection, and molecular biology detection, but virus isolation and identification are time-consuming, and traditional PCR and fluorescent PCR methods are limited in application in pet hospitals. The existing immunofluorescence detection method has low specificity, resulting in frequent false positive test results. Therefore, there is an urgent need in this field to establish a more sensitive and specific diagnostic antibody suitable for detecting serum antibodies infected with FHV. Summary of the invention

[0005] In view of this, the technical problem to be solved by the present invention is to provide an antibody for detecting feline herpes virus based on gB protein. The recombinant antibody based on FHV gB protein with high affinity and high specificity provided by the present invention can be used for specific detection such as indirect immunofluorescence and indirect ELISA.

[0006] The present invention provides a recombinant antibody against type I feline herpesvirus, wherein the three CDR regions of the light chain have the amino acid sequences shown in SEQ ID NOs: 1 to 3 in sequence;

[0007] The sequence shown in SEQ ID NO: 1 is: X L1SX L2 X L3 X L4 X L5 NX L6 ; Among them, X L1 For Q or E, X L2 V or I, X L3 E or Y or None, X L4 S or None, X L5 N or S, X L6 is N or Y;

[0008] The sequence shown in SEQ ID NO: 2 is: X L7 AS; where X L7 is F or A or G;

[0009] SEQ ID NO: 3 shows the sequence: X8 X L9 X L10 YX L11 X L12 X L13 X L14 X L15 X L16 X L17 X L18 X L19 ; Among them, X L8 V or H or L, X L9 G or Q, X L10 Y or T or E, X L11 Y or S, X L12 D or Y, X L13 G or N or T, X L14 S or N or K, X L15 D or V or A, X L16 T or G or None, X L17 F or N or None, X L18 F or G or none, X L19 A or None;

[0010] The three CDR regions of its heavy chain have the amino acid sequences shown in SEQ ID NOs: 4 to 6, in sequence;

[0011] SEQ ID NO: 4 shows the sequence: GX H1 X H2 LX H3 X H4 X H5 X H6 X H7 ; Among them, X H1 I or F, X H2 D or S, X H3 S or I, XH4 R or N or S, X H5 Y or N or G or S, X H6 G or D, X H7 is None or W;

[0012] The sequence shown in SEQ ID NO: 5 is: IX H8 X H9 X H10 X H11 X H12

[0013] X H13 X H14 X H15 X H16 X H17 RDX H18 X H19 X H20 X H21 X H22 X H23 X H24 X H25 SX H26 X H27 T; where X H8 None or D, X H9 None or A, X H10 None or G, X H11 None or T or S, X H12 None or S, X H13 None or G, X H14 None or S, X H15 None or T, X H16 None or W, X H17 None or Y, X H18 None or A, X H19 None or A or T, X H20 None or W, X H21 None or V, X H22 None or N, X H23 None or A, X H24 S or I or V or G, X H25 N or S, X H26 A or G, X H27 N or S;

[0014] The sequence shown in SEQ ID NO: 6 is: X H28 RX H29 X H30 X H31 X H32 X H33 X H34 X H35 X H36 XH37 X H38 ; Among them, X H28 G or A, X H29 None or W, X H30 None or S, X H31 T or G, X H32 I or V or T or S, X H33 T or Y, X H34 G or A, X H35 S or T or Y, X H36 G or L or Y, X H37 N or D, X H38 I or L.

[0015] Specifically, in some embodiments, the recombinant antibodies against type I feline herpesvirus include Ab-FHV gB-1, Ab-FHV gB-2, Ab-FHV gB-3, Ab-FHV gB-4, and Ab-FHV gB-5;

[0016] The three CDR regions of the light chain of Ab-FHV gB-1 have the amino acid sequences of QSVESNNN, FAS, and VGYYYDGSDTFFA, respectively; the three CDR regions of its heavy chain have the amino acid sequences of GIDLSRYG, ISNSANT, and GRTITGSGNI, respectively;

[0017] The three CDR regions of the light chain of Ab-FHV gB-2 have the amino acid sequences of ESISNY, AAS, and HQTYSYNNVGNG, respectively; the three CDR regions of its heavy chain have the amino acid sequences of GFSLSNNG, IISSGST, and ARGVYATLDI, respectively;

[0018] The three CDR regions of the light chain of Ab-FHV gB-3 have the amino acid sequences of ESINNY, AAS, and HQTYSYNNVGNG, respectively; the three CDR regions of its heavy chain have the amino acid sequences of GFSLSNNG, IISSGST, and ARGVYATLDI, respectively;

[0019] The three CDR regions of the light chain of Ab-FHV gB-4 have the amino acid sequences of QSVYSNNY, GAS, and LGEYSDTKA, respectively; the three CDR regions of its heavy chain have the amino acid sequences of GFSLSSGDW, IDAGTSGSTWYAAWVNAVSSGNT, and ARWSGTTAYYDL, respectively;

[0020] The three CDR regions of the light chain of Ab-FHV gB-5 have the amino acid sequences of QSVYSNNY, GAS and LGEYSDTKA, respectively; the three CDR regions of the heavy chain have the amino acid sequences of GFSLISSDW, IDAGSSGSTWYATWVNAGSSANT and ARWSGSTGYYDL, respectively.

[0021] The recombinant antibody provided by the present invention has an amino acid sequence of a light chain variable region as shown in any one of SEQ ID Nos: 7 to 11; and an amino acid sequence of a heavy chain variable region as shown in any one of SEQ ID Nos: 12 to 16. The light chain and the heavy chain are connected by a linker, and the amino acid sequence of the linker is shown in SEQ ID No: 17.

[0022] Specifically, in some embodiments, the amino acid sequence of the light chain variable region of the recombinant antibody Ab-FHV gB-1 is shown in SEQ ID No: 7, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No: 12;

[0023] The amino acid sequence of the light chain variable region of the recombinant antibody Ab-FHV gB-2 is shown in SEQ ID No: 8, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No: 13;

[0024] The amino acid sequence of the light chain variable region of the recombinant antibody Ab-FHV gB-3 is shown in SEQ ID No: 9, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No: 14;

[0025] The amino acid sequence of the light chain variable region of the recombinant antibody Ab-FHV gB-4 is shown in SEQ ID No: 10, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No: 15;

[0026] The amino acid sequence of the light chain variable region of the recombinant antibody Ab-FHV gB-5 is shown in SEQ ID No:11, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No:16.

[0027] The recombinant antibodies Ab-FHV gB-1, Ab-FHV gB-2, Ab-FHV gB-3, Ab-FHVgB-4 and Ab-FHV gB-5 provided by the present invention can specifically bind to antigens with high affinity. Indirect immunofluorescence confirmed that Ab-FHV gB-3 with the highest affinity can specifically bind to FHV virus and can be used for the specific detection of feline herpes virus FHV.

[0028] The present invention provides nucleic acids encoding the recombinant antibodies. Specifically, the nucleic acids encoding the monoclonal antibodies of the present invention may be DNA, RNA, cDNA or PNA. In an embodiment of the present invention, the nucleic acids are in the form of DNA. The DNA forms include cDNA, genomic DNA or artificially synthesized DNA. The DNA may be single-stranded or double-stranded. Nucleic acids may include nucleotide sequences with different functions, such as coding regions and non-coding regions such as regulatory sequences (e.g., promoters or transcription terminators). Nucleic acids may be linear or circular in topology. Nucleic acids may be, for example, a part of a vector (e.g., an expression or cloning vector), or a fragment. The nucleic acids may be obtained directly from natural sources, or may be prepared with the assistance of recombination, enzymatic methods or chemical techniques. The RNA form is mRNA obtained by gene transcription, etc.

[0029] The present invention provides an expression unit comprising a promoter, a terminator and the nucleic acid of the present invention.

[0030] Furthermore, the expression unit comprises an expression unit composed of the nucleic acid of the present invention in a single or multiple tandem form with the promoter and terminator, and the present invention is not limited to this.

[0031] The present invention also provides a transcription unit containing the nucleic acid or the expression unit, wherein the transcription unit refers to a DNA sequence starting from a promoter and ending at a terminator. A regulatory segment may also be included on both sides or between the promoter and the terminator, and the regulatory segment may include a promoter, an enhancer, a transcription termination signal, a polyadenylation sequence, a replication origin, a nucleic acid restriction site, and a homologous recombination site operably connected to the nucleic acid sequence, such as an enhancer of the promoter, a poly (A) signal, etc.

[0032] The present invention provides a recombinant vector comprising:

[0033] A vector backbone and the nucleic acid of the present invention;

[0034] Or a vector backbone and the expression unit described in the present invention.

[0035] Specifically, the recombinant vector of the present invention refers to a nucleic acid vector, which is a recombinant DNA molecule comprising a desired coding sequence and an appropriate nucleic acid sequence or element that is essential for the expression of an operably linked coding gene in a specific host organism. In this specification, "plasmid" and "vector" can sometimes be interchanged, because plasmid is the most commonly used vector form. However, the present invention is intended to include such other forms of expression vectors, which play an equivalent role, which are known or will become known in the art, including but not limited to: plasmids, phage particles, viral vectors and / or are only potential genome inserts.

[0036] The present invention provides a host, which comprises at least one of the following I) to III):

[0037] 1), secreting the recombinant antibody according to the present invention;

[0038] II), genome integration of the nucleic acid as described in the present invention or the expression unit as described in the present invention;

[0039] III), transfecting or transforming the recombinant vector as described in the present invention.

[0040] In the present invention, the recombinant vector is transfected or transformed into the host; the transformation method includes: chemical transformation and electrotransformation; the transfection method includes calcium phosphate coprecipitation, artificial liposome method, and viral transfection. The viral transfection includes adenovirus transfection, adeno-associated virus transfection, lentivirus transfection, etc. In some specific embodiments, the present invention constructs the host by PEI transfection.

[0041] Furthermore, the host described in the present invention includes bacteria, fungi, viruses or animals. The bacteria include Gram-positive bacteria and Gram-negative bacteria; the Gram-positive bacteria include but are not limited to Escherichia coli. The fungi include molds and yeasts; the yeasts include Saccharomyces cerevisiae, Saccharomyces cerevisiae, Pichia pastoris and Candida, etc. The viruses include but are not limited to adenovirus, adeno-associated virus, and lentivirus. The animals include humans, mice, rabbits, pigs, zebrafish, etc. In some specific embodiments, the host cells described in the present invention are eukaryotic cells HEK293f cells.

[0042] The present invention provides a method for preparing the recombinant antibody, comprising culturing the host as described in the present invention to obtain the recombinant antibody.

[0043] The present invention provides the use of the recombinant antibody, nucleic acid, expression unit, recombinant vector or host in preparing a type I feline herpes virus detection reagent or kit.

[0044] The present invention also provides a method for detecting type I feline herpesvirus, comprising using the antibody for detecting feline herpesvirus of the present invention for detection.

[0045] The methods provided by the present invention may be for diagnostic purposes or non-diagnostic purposes. For example, they include detection methods for diagnostic purposes performed on human or animal bodies, or samples isolated from human or animal bodies; and also include detection methods for scientific research or other non-diagnostic purposes performed on environmental samples or simulated samples.

[0046] The phage display library constructed by the present invention has extremely high application prospects in the screening of specific antibodies. The screened anti-FHV gB recombinant antibody Ab-FHV gB-3 has strong specificity, high affinity, can bind to the virus, can be used for the specific detection of FHV, and has good market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 The diagram shows the construction of the FHV gB-scFv phage library and the diversity analysis of the immune library provided in the embodiments of the present invention, wherein 1-A: antibody titer of New Zealand rabbits immunized 4 times; 1-B: amplified bands are VL gene library and VH gene library, M: Marker; 1: VH, 2: VL, 3: VL-linker-VH target band;

[0048] Figure 2 The present invention provides a method for screening high-affinity FHV gB-scFv, wherein: 2-A: PCR identification results after electroporation; 2-B: diversity of the antibody library after the first round of phage display screening; 2-C: diversity of the antibody library after the second round of phage display screening; 2-D: the second round of phage ELISA to determine the screening of scFv antibodies with high specificity binding to the antigen FHV gB;

[0049] Figure 3 The expression and affinity verification of Ab-FHV gB provided in the embodiment of the present invention are shown, wherein: 3-A: SDS-PAGE results of Ab-FHV gB, M: Marker, 1: Ab-FHV gB-1, 2: Ab-FHV gB-2, 3: Ab-FHV gB-3, 4: Ab-FHVgB-4, 5: Ab-FHV gB-5; 3-B: EC of Ab-FHV gB-1 antibody binding to antigen FHV gB 50 ; 3-C: EC binding of Ab-FHV gB-2 antibody to antigen FHV gB 50 ; 3-D: EC binding of Ab-FHV gB-3 antibody to antigen FHV gB 50 ; 3-E: EC binding of Ab-FHVgB-4 antibody to antigen FHV gB 50 ; 3-F: EC binding of Ab-FHV gB-5 antibody to antigen FHV gB 50 ;

[0050] Figure 4 The indirect immunofluorescence experiment results of Ab-FHV gB-3 recombinant antibody provided in the embodiment of the present invention and FHV virus are shown;

[0051] Figure 5The specific verification of the binding of the recombinant antibody Ab-FHV gB-3 provided in the embodiment of the present invention to FHV, FPV and FCV viruses is shown;

[0052] Figure 6 Figure 2 shows the plasmids pTT5-V5 and pTT5-V6 containing the rabbit antibody backbone mentioned in the examples of the present invention. DETAILED DESCRIPTION

[0053] The invention provides antibodies for detecting feline herpesvirus based on gB protein, and those skilled in the art can learn from this article content, and appropriately improve process parameters to realize. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. Method and application of the present invention have been described by preferred embodiments, and relevant personnel can obviously change or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention, to realize and apply the technology of the present invention.

[0054] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0055] Strains, plasmids, experimental animals and reagents:

[0056] Adult New Zealand rabbits were purchased from Yongkang Qingyuan Farm in Dingyuan County, Anhui Province; FHV gB protein was purchased from Nanjing GenScript Biotechnology Co., Ltd.; FHV-1 virus was preserved by our laboratory (GenBank: NC_013590.2); vectors pTT5-V5 and pTT5-V6 plasmids containing rabbit antibody backbones were preserved by our laboratory ( Figure 6 ); HRP-labeled recombinant protein A was purchased from Shanghai Bioengineering Co., Ltd.; HRP-labeled mouse anti-M13K07 phage was purchased from Chengdu Apak Biotechnology Co., Ltd.; HRP-labeled goat anti-rabbit IgG was purchased from Beijing Meikewande Biotechnology Co., Ltd.; pComb3XSS plasmid and Escherichia coli DH5α competent cells were purchased from Shandong Hertz Biotechnology Co., Ltd.; M13K07 helper phage and Escherichia coli ER2738 competent cells were purchased from Nanjing Heming Yinggu Biotechnology Co., Ltd.; SDS-PAGE protein gel kit was purchased from Yazyme Biotechnology Co., Ltd.; penicillin-streptomycin solution was purchased from GE (for cell culture); Freund's adjuvant was purchased from Sigma; ClonExpress II One Step Cloning Kit was purchased from Nanjing Novozyme Biotechnology Co., Ltd.; Premixtaq, Plasmid mini kit, Gel Extraction and transfection reagents were all purchased from TaKaRa.

[0057] The amino acid sequences of the heavy chain variable regions of the single-chain antibody FHV gB-scFv-1 and the recombinant antibody Ab-FHV gB-1 are:

[0058] QSVKESGGRLVTPGTPLTLTCTVSGIDLSRYGMSWVRQAPGKGLEWIGYISNSANTY YASWASGRFTISKTSTTVDLKITSPTTEDTATYFCGRTITGSGNIWGPGTLVTVSS

[0059] The amino acid sequences of the light chain variable regions of the single-chain antibody FHV gB-scFv-1 and the recombinant antibody Ab-FHV gB-1 are:

[0060] DGVLTQTPSSTSAAVGGTVTINCQSSQSVESNNNLAWYQQKPGQPPKLLIYFASKLA SGVPSRFSGSGSGTQFALTISDLECDDAATYYCVGYYYDGSDTFFAFGGGTEVVVK

[0061] The amino acid sequences of the heavy chain variable regions of the single-chain antibody FHV gB-scFv-2 and the recombinant antibody Ab-FHV gB-2 are:

[0062] QSVKESGGRLVTPGTPLTLTCTVSGFSLSNNGMGWVRQAPGEGLEWIGTIISSGSTY YASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARGVYATLDIWGPGTLVTVSS

[0063] The amino acid sequences of the light chain variable regions of the single-chain antibody FHV gB-scFv-2 and the recombinant antibody Ab-FHV gB-2 are:

[0064] DGVMTQTPASVEAAVGGTVTIKCQASESISNYLSWYQQKPGQPPKLLIYAASYLAS GVPSRFSGSGSGTEFTLTISGVQCDDAATYYCHQTYSYNNVGNGFGGGTEVVVK

[0065] The amino acid sequences of the heavy chain variable regions of the single-chain antibody FHV gB-scFv-3 and the recombinant antibody Ab-FHV gB-3 are:

[0066] QSVKESGGRLVTPGTPLTLTCTVSGFSLSNNGMGWVRQAPGEGLEWIGTIISSGSTY YASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARGVYATLDIWGPGTLVTVSS

[0067] The amino acid sequences of the light chain variable regions of the single-chain antibody FHV gB-scFv-3 and the recombinant antibody Ab-FHV gB-3 are:

[0068] DGVLTQTPSPVEAAVGGTVTIKCQASESINNYLSWYQQKPGQPPKLLIYAASYLASGVPSRFSGSGSGTEFTLTISGVQCDDAATYYCHQTYSYNNVGNGFGGGTEVVVK

[0069] The amino acid sequences of the heavy chain variable regions of the single-chain antibody FHV gB-scFv-4 and the recombinant antibody Ab-FHV gB-4 are:

[0070] ESGGGAEGGLVKPGGSLELCCKASGFSLSSGDWICWVRQAPGKGLEWIGCIDAGTSGSTWYAAWVNAVSSGNTWYATWVNGRFTLSRDIDQNTGCLQLNSLTAADTAIYYCARWSGTTAYYDLWGQGTPVTVSS

[0071] The amino acid sequences of the light chain variable regions of the single-chain antibody FHV gB-scFv-4 and the recombinant antibody Ab-FHV gB-4 are:

[0072] DGVMTQTPASVSAAVGGTVTINCQASQSVYSNNYLSWFQQKPGQPPKQLIYGASK LASGVPSRFKGSGSGTQFTLTINGVQCDDAATYYCLGEYSDTKAFGGGTEVVVK

[0073] The amino acid sequences of the heavy chain variable regions of the single-chain antibody FHV gB-scFv-5 and the recombinant antibody Ab-FHV gB-5 are:

[0074] QSGGGAEGGLVKPGGSLELCCKASGFSLISSDWICWVRQAPGKGLEWIGCIDAGSSGSTWYATWVNAGSSANTWYATWVNGRFTLSRDIDQSTGCLQLNSLTAADTAIYYCARWSGSTGYYDLWGQGTPVTVSS

[0075] The amino acid sequences of the light chain variable regions of the single-chain antibody FHV gB-scFv-5 and the recombinant antibody Ab-FHV gB-5 are:

[0076] DGVLTQTPSPVSAAVGGTVTINCQASQSVYSNNYLSWFQQKPGQPPKLLIYGASKL ASGVPSRFKGSGSGTQFTLTINGVQCDDAATYYCLGEYSDTKAFGGGTEVVVK

[0077] Amino acid sequence of linker:

[0078] GGGGSGGGGGGSSRSS

[0079] Primer sequences:

[0080] Construction of VH-scFv-F1 library

[0081] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGTCGKTGGAGGAGTCC-3'

[0082] Construction of VH-scFv-F2 library

[0083] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGWCAGTGAAGGAGTCC-3'

[0084] Construction of VH-scFv-F3 library

[0085] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGTCGCTGGRGGAGTCC-3'

[0086] Construction of VH-scFv-F4 library

[0087] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGTCGGTGGAGGAGTCC-3'

[0088] Construction of VH-scFv-R1 library

[0089] 5'-AGGAGGCTATTGGCCGGCCTGGCCTGARGAGAYGGTGACCAGGGTGCC-3'

[0090] Construction of VH-scFv-R2 library

[0091] 5’-AGGAGGCTATTGGCCGGCCTGGCCGCAGCAGGGGGCCAGTGGGAAGACT GAC-3’

[0092] Library construction of VL-scFv-F1

[0093] 5’-AAAAGAGGCCCAGGCGGCCGAGCTCGTGMTGACCCAGACTCCA-3’

[0094] Library construction of VL-scFv-F2

[0095] 5’-AAAAGAGGCCCAGGCGGCCGAGCTCGATMTGACCCAGACTCCA-3’

[0096] Library construction of VL-scFv-F3

[0097] 5’-AAAAGAGGCCCAGGCGGCCGCYCAAGTGCTGACCCAG-3’

[0098] Library construction of VL-scFv-F4

[0099] 5’-AAAAGAGGCCCAGGCGGCCGCCCWAGTGATGACCCAG-3’

[0100] Library construction of VL-scFv-R1

[0101] 5’-GGAAGATCTAGAGGAACCACCCCCACCACCGCCCGAGCCACCGCCACCTTTGATTTCCACATTGGTGCC-3’

[0102] Library construction of VL-scFv-R2

[0103] 5’-GGAAGATCTAGAGGAACCACCCCCACCACCGCCCGAGCCACCGCCACCTAGGATCTCCAGCTCGGTCCC-3’

[0104] Overlap PCR-FP

[0105] 5’-GAGGAGGAAAAAGAGGCCCAGGCGGCC-3’

[0106] Overlap PCR-RP

[0107] 5’-AGAGGAGGCTATTGGCCGGCCTGGCC-3’

[0108] Verifying pComb3XSS-FP

[0109] 5'–GCTGGTTTCGCTACCGTGGCCCAGGCGGCC-3'

[0110] Verifying pComb3XSS-RP

[0111] 5'–GTGATGGTGATGGTGCTGGCCGGCCTGGCC-3'

[0112] The present invention will be further described below in conjunction with embodiments:

[0113] Example 1 Animal Immunization

[0114] Healthy adult New Zealand rabbits were selected for the experiment. Blood was collected from the vein before immunization and the serum was separated as a negative control. 5 TCID 50 / mL FHV virus was injected into the back of the neck of New Zealand rabbits, and immunized once a week for a total of 4 times. 0.5mL of venous blood was collected before each immunization on days 0, 7, 14, and 21, and the serum was separated and stored. 7 days after the fourth immunization (i.e., day 28), 0.5mL of venous blood was collected and the serum was separated and stored. ELISA results showed that the serum antibody titer increased significantly after the first immunization, and the antibody titer of the second immunization was close to 9×10 4 , after three free times, it reaches 2×10 5 The titer of the four immune serum increased significantly, exceeding 5×10 5 , compared with the serum antibody titer before immunization, all of them were significantly increased (1-A). On the 28th day, the New Zealand rabbits were killed, 0.5 mL of blood was collected to separate the serum for preservation, and the spleen was removed by dissection for lymphocyte separation.

[0115] Example 2 Extraction of total RNA from lymphocytes and amplification of antibody light and heavy chain genes

[0116] Total RNA of lymphocytes was extracted with Trizol reagent, and cDNA was synthesized by reverse transcription using Oligo (dT) as a template. Primer sequence combinations were designed based on the light and heavy chain framework regions of the rabbit antibody sequence, and PCR was performed to amplify the coding regions of antibody VH and VL. The PCR reaction conditions were: 95°C pre-denaturation for 5 minutes, 95°C denaturation for 30 seconds, 55°C annealing for 30 seconds, 72°C extension for 60 seconds, and after 35 cycles, 72°C extension for another 5 minutes. The PCR product was verified by 1% agarose gel electrophoresis to have a target band around 400 bp, and was purified and recovered for later use (1-B).

[0117] Example 3 Construction of FHV gB-scFv antibody library

[0118] Using purified VH and VL as templates, a linker (sequence: SEQ ID NO. 17) was inserted between VH and VL after overlapping PCR to synthesize the scFv fragment VL-linker-VH, which contained sfiI restriction enzyme sites at both ends of the sequence.

[0119] Overlap extension first round PCR: without primers, denaturation at 98℃ for 1min, annealing at 45℃ for 30s, extension at 72℃ for 1min, repeat 10 cycles, and finally at 72℃ for 5min. Add primers overlap PCR-FP and overlap PCR-RP, denaturation at 98℃ for 30s, then renaturation at 58℃ for 30s, extension at 72℃ for 1min, and then extension at 72℃ for another 5min after 30 cycles. The PCR product was recovered by gel recovery through 1% agarose gel electrophoresis, with a band of about 800bp (1-B), and stored at -20℃. The overlapping PCR primer sequence is.

[0120] The PCR products and pComb3XSS vector after gel recovery were digested with restriction endonuclease sfiI at 50°C for 30 min, respectively. The digestion products were verified by 1% agarose gel electrophoresis, then recovered and purified on the column and ligated with T4 DNA ligase to obtain the FHV gB-scFv-pComb3XSS library. The ligation products were transformed into ER2738 competent cells, and positive clones were screened with tetracycline and ampicillin resistant 2YT (2×Yeast extract and Tryptone) solid culture medium. 20 single clones in the library were randomly selected for PCR identification, and the antibody library recombination rate was calculated to be 50% (2-A). All clones on the solid culture medium were washed off with 2YT culture medium and stored at 4°C.

[0121] Example 4 Amplification of bacteriophage

[0122] Take 2 mL of the bacterial culture solution of all clones washed with 2YT medium and inoculate it into 50 mL of 2YT liquid medium. Activate at 37°C and 200 rpm until OD 600 When the concentration reaches 0.8-1.0, add the final concentration of 1×10 12 pfu / mL of M13K07 helper phage for infection, let stand for 30 minutes, then add kanamycin (final concentration of 50μg / mL), and culture overnight at 30℃200rpm. The next day, centrifuge at 10000rpm4℃ for 20 minutes, retain the supernatant and add 1 / 2 volume of PEG8000 to it, let stand on ice for 2 hours to precipitate the phage. Centrifuge at 10000rpm4℃ for 20 minutes, discard the supernatant. Resuspend the precipitate with 5mL PBS, add 3mL PEG8000 to re-precipitate, repeat the centrifugation operation, resuspend the precipitate with 4mL PBS, filter and sterilize, and store at 4℃ for use.

[0123] Example 5 FHV gB-scFv screening

[0124] Biotinylate the FHV gB protein in advance. After mixing the amplified FHV gB-scFv library phage, Dynabeads M-280 magnetic beads labeled with FHV gB protein and 2% skim milk powder blocking solution, incubate at 25℃±5℃ for 1h, and wash the magnetic beads with PBST 5-10 times. Elute the phage on the surface of the magnetic beads with 0.1M Glycine-HCl (pH=2.0), and neutralize with 1M Tris to pH 7.0 after elution. Infect ER2738 competent cells in the logarithmic growth phase with the neutralized phage after elution, culture and enrich on 2YT solid medium, and harvest the colonies for the next round of screening.

[0125] The above experiment was repeated twice. 20 monoclones were randomly selected from the two rounds of enrichment affinity screening libraries for PCR verification. The results showed that the positive rate of the constructed FHV gB-scFv library in the first round of panning was 80%, and the positive rate in the second round of panning was 85% (2-B and 2-C).

[0126] Example 6 Phage ELISA

[0127] Coat the ELISA plate with FHV gB antigen at a concentration of 50 μg / mL per well at 4°C overnight. Wash 5 times with PBST solution containing 0.05% Tween-20, discard PBST, add 2% skim milk powder blocking solution, and block at 37°C for 1 hour. Wash 5 times with PBST solution, pat dry the residual liquid in the well, mix the supernatant of the positive clone antibody to be screened and 2% skim milk powder blocking solution in a ratio of 3:2, stand at 25°C±5°C for 10 minutes to remove interference, add to the ELISA plate, and incubate at 37°C for 1 hour. Wash 5 times with PBST solution, pat dry the residual liquid in the well, add HRP-labeled mouse anti-M13K07 antibody (diluted 1:3000 with blocking solution), and incubate at 37°C for 1 hour. Wash with PBST solution 5 times, pat dry the residual liquid in the wells, add TMB colorimetric solution, keep it in the dark for 15 minutes, add 2 mol / L H2SO4 to stop the color development, and read the absorbance at 450 nm (Table 1). Figure 2 In 2-D Display, select OD 450 The 15 antibodies with the highest PCR values ​​were sequenced, and finally 5 antibodies with different sequences were obtained for subsequent experiments.

[0128] Table 1 Affinity test of FHV gB-scFv and antigen FHV gB

[0129] 1.23 0.452 0.561 1.19 1.823 0.31 0.24 1.431 1.568 1.956 2.65 1.85 1.02 1.26 1.74 0.657 0.987 0.81 0.745 0.728 1.91 0.512 0.539 0.82 0.614 0.257 0.9823 0.237 1.72 0.2365 0.562 1.235 1 0.45 1.8 0.327 1.7623 1.634 0.169 0.73 0.83 0.638 0.37 0.2376 1.013 1.73 0.5623 0.52 0.2635 0.676 0.67734 1.36 1.87 2.167 0.3478 0.87 1.986 0.476 0.76 0.45 0.4356 1.653 0.764 0.23 1.34 0.873 1.546 0.765 0.435 0.634 0.653 0.37 0.456 0.987 1.5 1.234 0.345 0.84 0.57 0.765 0.64 1.476 0.86 0.147 1.56 0.133 0.5778 0.427 0.78 0.8274 0.2178 1.738 0.218 1.38 0.048 0.032

[0130] Example 7 Recombination, expression and purification of FHV gB recombinant antibody Ab-FHV gB

[0131] The VH and VL sequences of five single-chain antibody FHV gB-scFvs were amplified and purified, and the pTT5-V5 and pTT5-V6 vectors containing rabbit antibody backbones were double-digested with EcoRI and HindIII restriction endonucleases, and antibody expression plasmids VH-pTT5-V5-1 to VH-pTT5-V5-5 and VL-pTT5-V6-1 to VL-pTT5-V6-5 were obtained by homologous recombination. The recombinant plasmids VH-pTT5-V5-1 to VH-pTT5-V5-5 and VL-pTT5-V6-1 to VL-pTT5-V6-5 were matched one by one and transfected into HEK293f cells by PEI for eukaryotic expression. After 48 hours, the culture supernatant was collected by centrifugation at 10000 rpm and 4°C for 20 minutes, and the antibody was purified using a Protein A affinity chromatography column. Finally, the fusion protein was preserved in PBS solution and named Ab-FHV gB-1, Ab-FHV gB-2, Ab-FHV gB-3, Ab-FHV gB-4, and Ab-FHV gB-5, respectively.

[0132] The purified samples were added to the reduced protein loading buffer and subjected to SDS-PAGE electrophoresis after denaturation. Figure 3 As shown in 3-A, the disulfide bonds between the heavy chain and the light chain of the antibody were reduced, and the target bands were detected at around 50 kDa and 25 kDa, which was consistent with the expected results.

[0133] Example 8 Indirect ELISA to detect the binding of recombinant antibody Ab-FHV gB to FHV gB antigen

[0134] The affinity of Ab-FHV gB to antigen FHV gB was determined by indirect ELISA. Antigen was added to the ELISA plate and incubated at 4°C overnight, and blocked with 2% skim milk powder blocking solution at 37°C for 2h. The antibody was diluted 12 times with 2% skim milk powder and added to the wells, and incubated at 37°C for 1h. HRP-labeled goat anti-rabbit IgG secondary antibody was added, and TMB was used for color development, and the absorbance at a wavelength of 450nm was detected in an ELISA instrument (Tables 2 to 6).

[0135] The binding effect of the above antibody Ab-FHV gB was tested as follows Figure 3 As shown in Figures 3-B to 3-F, the dose-effect curves were successfully fitted with the regression model. The five Ab-FHV gB antibodies were able to effectively bind to the FHV gB protein, and the antibody Ab-FHV gB-3 had the highest affinity. The EC binding to the recombinantly expressed FHV gB protein was 50 is 1.113×10 -1 μg / mL, indicating that the recombinant antibody was active and had good affinity, and Ab-FHV gB-3 was used in subsequent experiments.

[0136] Table 2 EC binding of Ab-FHV gB-1 to antigen FHV gB 50

[0137]

[0138] Table 3 EC50 of Ab-FHV gB-2 binding to antigen FHV gB

[0139]

[0140] Table 4 EC binding of Ab-FHV gB-3 to antigen FHV gB 50

[0141]

[0142] Table 5 EC binding of Ab-FHV gB-4 to antigen FHV gB 50

[0143]

[0144] Table 6 EC binding of Ab-FHV gB-5 to antigen FHV gB 50

[0145]

[0146] Example 9 Indirect immunofluorescence detection of recombinant antibodies

[0147] Use EMEM containing 10% FBS to revive CRFK adherent cells. When the cell confluency reaches 80-90%, inoculate FHV venom with an MOI of 0.1 and co-infect and culture in a 37°C 5% CO2 incubator. Set up a virus-negative group as a control. Add an equal volume of 2% FBS EMEM and culture in a cell culture incubator. Wash the cells 3 times with PBS after 24 hours. Add 500μL 4% paraformaldehyde to fix the cells, and wash the cells 3 times with PBS after 30 minutes. Add 500μL 0.1% TritonX100, and wash the cells 3 times with PBS after 15 minutes. Block with PBS containing 3% sodium caseinate at 37°C for 1 hour and wash 3 times with PBS. The recombinant antibody Ab-FHV gB-3 was used as the primary antibody for indirect immunofluorescence at a concentration of 0.5 μg / mL and incubated at 37°C for 1 h. The secondary antibody was goat anti-rabbit FITC and incubated at 37°C for 1 h. The plate was washed 3 times, 500 uL DAPI was added for staining for 20 min, and the plate was washed 3 times with PBS and observed using an inverted fluorescence microscope. Figure 4As shown, the recombinant antibody Ab-FHV gB-3 and the FHV virus positive sample showed obvious specific green fluorescence signal, while the virus negative control group had no fluorescence signal. This proves that the recombinant antibody Ab-FHV gB-3 can specifically bind to the FHV virus and can be used for the specific detection of feline herpes virus FHV.

[0148] Example 10 Antibody specificity verification

[0149] Use 1×10 4 TCID 50 / mL of FPV, FCV, and FHV cytotoxic supernatant was coated on the ELISA plate and incubated at 4°C overnight. Wash 5 times with PBST solution containing 0.05% Tween-20, discard PBST, add 2% skim milk powder blocking solution, and block at 37°C for 1h. Wash 5 times with PBST solution, pat dry the residual liquid in the wells, mix the recombinant antibody Ab-FHV gB-3 and 2% skim milk powder blocking solution in a ratio of 3:2, let stand at 25°C±5°C for 10min to remove interference, add to the ELISA plate, and incubate at 37°C for 1h. Wash 5 times with PBST solution, pat dry the residual liquid in the wells, add HRP-labeled goat anti-rabbit IgG secondary antibody, and incubate at 37°C for 1h. Wash 5 times with PBST solution, pat dry the residual liquid in the wells, add TMB colorimetric solution, let stand in the dark for 15min, add 2mol / LH2SO4 to stop color development, and read the absorbance at 450nm (Table 7). Figure 5 As shown, the recombinant antibody Ab-FHV gB-3 showed good affinity with the FHV virus, and had poor binding levels with the FPV and FCV viruses, showing FHV virus specificity. This proved that the recombinant antibody Ab-FHV gB-3 can specifically bind to the FHV virus, can be used for the specific detection of feline herpesvirus FHV, and will not be confused with the specific detection of feline parvovirus and feline calicivirus. It is an excellent antibody for feline herpesvirus detection.

[0150] Table 7 Verification of specific binding of Ab-FCV VP1-4 to FCV, FPV, and FHV

[0151] 1 2 3 FWf 2.3106 2.1627 2.3135 FPV 0.0461 0.0397 0.0472 FCV 0.0502 0.0542 0.0407

[0152] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A recombinant antibody against type I feline herpesvirus, characterized in that: The amino acid sequences of the three CDR regions of its light chain are QSVESNNN, FAS and VGYYYDGSDTFFA; the amino acid sequences of the three CDR regions of its heavy chain are GIDLSRYG, ISNSANT and GRTITGSGNI; or the amino acid sequences of the three CDR regions of its light chain are ESISNY, AAS and HQTYSYNNVGNG respectively; the amino acid sequences of the three CDR regions of its heavy chain are GFSLSNNG, IISSGST and ARGVYATLDI respectively; or the amino acid sequences of the three CDR regions of its light chain are ESINNY, AAS and HQTYSYNNVGNG respectively; the amino acid sequences of the three CDR regions of its heavy chain are GFSLSNNG, IISSGST and ARGVYATLDI respectively; or the amino acid sequences of the three CDR regions of its light chain are QSVYSNNY, GAS and LGEYSDTKA respectively; the amino acid sequences of the three CDR regions of its heavy chain are GFSLSSGDW, IDAGTSGSTWYAAWVNAVSSG NT and ARWSGTTAYYDL respectively; Or the amino acid sequences of the three CDR regions of its light chain are QSVYSNNY, GAS and LGEYSDTKA respectively; the amino acid sequences of the three CDR regions of its heavy chain are GFSLISSDW, IDAGSSGSTWYATWVNAGSSA NT and ARWSGSTGYYDL respectively.

2. The recombinant antibody according to claim 1, characterized in that: The amino acid sequence of its light chain variable region is shown in SEQ ID No: 7, and the amino acid sequence of its heavy chain variable region is shown in SEQ ID No: 12; or The amino acid sequence of its light chain variable region is shown in SEQ ID No: 8, and the amino acid sequence of its heavy chain variable region is shown in SEQ ID No: 13; or The amino acid sequence of its light chain variable region is shown in SEQ ID No: 9, and the amino acid sequence of its heavy chain variable region is shown in SEQ ID No: 14; or The amino acid sequence of its light chain variable region is shown in SEQ ID No: 10, and the amino acid sequence of its heavy chain variable region is shown in SEQ ID No: 15; or The amino acid sequence of its light chain variable region is shown in SEQ ID No:11, and the amino acid sequence of its heavy chain variable region is shown in SEQ ID No:

16.

3. A nucleic acid encoding the recombinant antibody according to claim 1 or 2.

4. An expression unit, characterized in that It comprises a promoter, a terminator and the nucleic acid according to claim 3.

5. A recombinant vector, characterized in that: include: A vector backbone and the nucleic acid of claim 3; or A vector backbone and the expression unit according to claim 4.

6. A host, characterized in that It includes at least one of the following I) to III): 1), secreting the recombinant antibody according to claim 1 or 2; II), genomic integration of the nucleic acid according to claim 3 or the expression unit according to claim 4; III), transfect or transform the recombinant vector as described in claim 5.

7. The host according to claim 6, characterized in that Includes eukaryotic cells and bacteria.

8. The method for preparing the recombinant antibody according to claim 1 or 2, characterized in that: The method comprises culturing the host according to claim 6 or 7 to obtain the recombinant antibody.

9. Use of the recombinant antibody described in claim 1 or 2, the nucleic acid described in claim 3, the expression unit described in claim 4, the recombinant vector described in claim 5 or the host described in claim 6 or 7 in preparing a type I feline herpes virus detection reagent or a kit.